Examen #2 Repaso PDF

rose If causesdilation........................................................................................................................................................ EE.EE eErIEE................................................ anaptzer.......................... another name....................

rose If causesdilation........................................................................................................................................................ EE.EE eErIEE................................................ anaptzer.......................... another name.......................................... of nor epi.......................................... enhancesthe release fgyyyifqgy.gg.......................................... f ff................................................. Epinephrine................................................................................................................ 2............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. in disinose... does work t.infePffsemmytane Lighton.......... yes.................................................... yygfjg.gg no.............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. 1994......................................................................... pre............................................................... expansion ghost Dark..................... In test.......................................................................................... ganglionic................................................................................................................................................................................................................................................................................................................................................................................. o........................................................................................................................................................................................................................... Commercially................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. butnotentirely................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. T.IT EefyeBYfIIf'y fgf usefcoma....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Compization All beta blockers. are.... lipophilic........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Gene................................................................................................................................................................................................................................................................ watydrofilic............................................................................... ty systolic... muchosson.......................................................................................................................................................................................................................................................................................................................................................... May 2 tiPos y Parasympathetic System Cholinergic Agonist............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... a............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 858bn......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Bit P tf predominates inyours meet........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ Effie ns............................................................................................................................................................................................................................................. Egg release Found primarily inthe....... gastricparietted................ andstomach........................................................................................ basalgangliaamygdalahippocampus substantia nigra midbrain function new tdotions ifeng.gg................................................................................................................................................................... 2 5........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ d esto...................................... esta................................................................................................................................................................................................................................................................................................................................................................................................................................................................... voluntary................................................................................................................................................................................................................................. no... Actions Actions vagus................................................................................................................................................................. R.. causes nerve............................................................................................................................................................................................................................................................................................................................................................................... involuntary.................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. Salagan tablet................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... longitudinal fibers van scleral spur pigmentary...... 2 glaucoma Sjogren'ssyndrome............................................................................................................................................................................................................ oral administration xerostomia xerophthalmia................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. Inhibitors.................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. choice ese..................................................................................................................................................................................................................................................................................................................... a................................................... and.. 8 fÉ Febkmyotic ny. f 4.............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. sed covalent fororgano phosphate poisining................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................